Tailored Communication to Reduce Cardiovascular Risk
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 464
- 试验地点
- 2
- 主要终点
- Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction
研究概览
简要总结
The primary goal of the trial is to test the feasibility and efficacy of a cardiovascular disease quality improvement system that couples EMR-based patient identification with individually tailored patient messages. The study will test the hypothesis that that a tailored patient-directed approach to cardiovascular risk reduction integrated into patients' primary care delivery site will improve control of elevated low-density lipoprotein cholesterol and other card iac risk factors more than routine care alone for patients at intermediate or high risk for cardiovascular disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 40 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 40 to 79 years
- •medication list does not include an active lipid lowering medication
- •the patient does not have a diagnosis in the past medical history, active problem list or past visit encounter of coronary heart disease, heart failure, stroke, diabetes mellitus, or peripheral arterial disease
- •the patient has an enrolled study physician recorded as his/her primary care physician
- •the patient has an LDL cholesterol that meets one or more of the criteria listed below.
- •LDL cholesterol >= 130 mg/dl and estimated Framingham Risk Score 10-20% LDL cholesterol >= 100 mg/dl and estimated Framingham Risk Score >20% LDL cholesterol >= 160 mg/dl and estimated Framingham Risk Score 5% to <10%.
排除标准
- •Age <40 or >79 years
- •medication list includes an active lipid lowering medication
- •the patient hase a diagnosis in the past medical history, active problem list or past visit encounter of coronary heart disease, heart failure, stroke, diabetes mellitus, or peripheral arterial disease
- •the patient does not have an enrolled study physician recorded as his/her primary care physician
- •the patient does not have an LDL cholesterol that meets one or more of the criteria listed below.
- •LDL cholesterol >= 130 mg/dl and estimated Framingham Risk Score 10-20% LDL cholesterol >= 100 mg/dl and estimated Framingham Risk Score >20% LDL cholesterol >= 160 mg/dl and estimated Framingham Risk Score 5% to <10%.
结局指标
主要结局
Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction
时间窗: 9 months
Significant LDL cholesterol reduction at 9 months Definition: Percentage of patients with LDL-C repeated and which is at least 30 mg/dl lower than baseline
次要结局
- Frequency of Clinical Encounters(9 months)
- Percentage of Patients With Uncontrolled Hypertension Who Had an Increase in the Number of Antihypertensive Medication Drug Classes Prescribed(9 months)
- Medication Prescriptions for Dyslipidemia(9 months)
- Presence of an Aspirin Prescription(9 months)
研究者
Stephen Persell
Assistant Professor
Northwestern University